Brand Institute review

Strong — 4 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 23% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Excellent 4 · Strong 10 · Adequate 3. The typical agency here scores Strong, and 4 of them score higher than this one.

What this dimension measures: Names the firm created that are verifiably in use by real companies — the strongest evidence this category can offer, because a shipped name is public.

Scores high — Attributed, checkable names for recognisable clients score 4-5.

Scores low — Case studies without the client's confirmation, or a portfolio dominated by decades-old wins, score 2-3: naming credits are notoriously contested and old glory says little about the current team. No attributable names scores 2.

What we found — The about page attributes a long list of real, in-market pharmaceutical brands to the firm - Victoza, Saxenda, Kyleena, Comirnaty, Fasenra, Fetroja, Nyxoid, Restasis, Nucala, REZDIFFRA, EPKINLY, UBRELVY, XCOPRI - and names clients including Pfizer, Roche, Amgen, AstraZeneca, GSK, Sandoz, Shionogi, Mundipharma and Celltrion. The press release archive carries dated, client-joint announcements (Arvinas / bavdegalutamide, Dec 5 2022; Bavarian Nordic / JYNNEOS, Nov 28 2022; TADLIQ, FUROSCIX, VEGZELMA, APONVIE) and is current, with the most recent release dated Apr 17 2026. The portfolio is not decades-old glory: 2025 jurisdiction-level approval rates and 2026 releases show a working current practice. Held off Excellent because the specific name credits rest largely on the firm's own press releases - the Wikipedia entry on the company carries an explicit maintenance warning that it may rely excessively on sources too closely associated with the subject, and a FiercePharma piece on the Comirnaty naming returned 403 so it could not be read first-hand. Three verified Clutch reviews independently confirm the healthcare regulatory-naming practice is real, but not individual credits. That is the high band above, which is why it scored Strong.

On the record — “The press release archive is current and carries dated, client-joint naming announcements, including Arvinas / bavdegalutamide (Dec 5 2022) and Bavarian Nordic / JYNNEOS (Nov 28 2022); the most recent release is dated Apr 17 2026.” brandinstitute.com ↗

On the record — “The Wikipedia entry for the company carries an explicit maintenance warning that it may rely excessively on sources too closely associated with the subject, with many pharmaceutical name attributions linking to Brand Institute's own materials rather than independent verification.” en.wikipedia.org ↗

Evidence: partly checkable — corroborated in part against the sources below; the remainder rests on the agency’s own account.

Strong — 4 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 19% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Excellent 1 · Strong 9 · Adequate 7. The typical agency here scores Strong, and 1 of them score higher than this one.

What this dimension measures: A published, specific process: how territories are developed, how many candidates are generated, and — critically — linguistic and cultural screening across the markets the client sells in. Weight specificity: the firms that do this well tend to write about it in detail, so vagueness is informative.

Scores high — A described multi-market linguistic check with named steps scores 4-5.

Scores low — A generic 'we brainstorm then check' description scores 2-3. No described method scores 2.

What we found — Unusually specific for this category, and named at the step level rather than described in the abstract. Screening runs across a stated 268 international trademark databases using BrandReality (a pharma-in-use legal prescreen) and a Common-Law Prescreen; name safety is checked against the FDA POCA system with a stated pass condition that candidates not exceed a 75 percent combined phonetic and orthographic score. Linguistic evaluation is performed by in-country native-speaking professionals in the client's primary markets, which is the multi-market check this dimension asks for. Name recommendations are tiered by regulatory viability and research results are benchmarked to historical norms. The medical device page describes a three-stage sequence: consultation, creative development plus regulatory screening, then linguistic validation and market testing. The regulatory layer is a genuine differentiator - the Drug Safety Institute subsidiary (established 2004) is staffed by former FDA, EMA, Health Canada, AMA and WHO naming officials and publishes 2025 approval rates by jurisdiction (FDA 88 percent, EMA 76 percent, Health Canada 97 percent, Japan 76 percent, USAN 76 percent, INN 79 percent). Short of Excellent because how naming territories are developed and how many candidates are generated are never described, and every step above is self-published. That is the high band above, which is why it scored Strong.

On the record — “The Drug Safety Institute subsidiary (established 2004) is staffed by former officials of the FDA, EMA, Health Canada, AMA and WHO, and publishes 2025 approval rates by jurisdiction: FDA 88 percent, EMA 76 percent, Health Canada 97 percent, Japan 76 percent, USAN 76 percent, INN 79 percent.” brandinstitute.com ↗

On the record — “Trademark and name-safety screening is described with named mechanisms and a stated threshold: 268 international trademark databases, BrandReality pharma-in-use legal prescreen, common-law prescreen, and FDA POCA scoring with candidates required not to exceed a 75 percent combined phonetic and orthographic score.” brandinstitute.com ↗

Evidence: vendor stated — the agency’s own claim, recorded as theirs rather than ours.

Adequate — 3 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 14% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Excellent 4 · Strong 11 · Adequate 2. The typical agency here scores Strong, and 15 of them score higher than this one.

What this dimension measures: What the firm does before candidates reach the client: knockout searches, class strategy, and how it hands off to trademark counsel.

Scores high — A stated pre-screening step with honest boundaries — screening is not legal clearance, and firms that say so score better than firms that imply it is — scores 4-5.

Scores low — Silence on trademark process scores 2, because presenting unscreened names wastes the one thing this purchase buys. Any implication that the firm's screening substitutes for counsel is a red flag, scored 1-2.

What we found — A pre-screening step is clearly stated and staffed: trademark searches are run by an in-house team of attorneys and paralegals, using the BrandReality pharma-in-use legal prescreen and a common-law prescreen across 268 databases, with stated report customization. That is well above silence. It does not reach the top band because the firm never states the boundary the rubric rewards - nowhere on the pages read does it say that its screening is a prescreen rather than legal clearance, nor does it describe a handoff to the client's trademark counsel or any class strategy. Employing attorneys in-house makes that silence more consequential, not less, since a buyer could reasonably read it as clearance. Equally, the firm does not affirmatively claim its screening substitutes for counsel, so this is an omission rather than the misrepresentation the rubric scores 1-2. That is between the two bands, which is why it scored Adequate.

On the record — “Trademark searches are performed by an in-house team of attorneys and paralegals; no page read states whether this constitutes legal clearance or a prescreen handed to the client's counsel.” brandinstitute.com ↗

On the record — “Trademark and name-safety screening is described with named mechanisms and a stated threshold: 268 international trademark databases, BrandReality pharma-in-use legal prescreen, common-law prescreen, and FDA POCA scoring with candidates required not to exceed a 75 percent combined phonetic and orthographic score.” brandinstitute.com ↗

Evidence: vendor stated — the agency’s own claim, recorded as theirs rather than ours.

Weak — 2 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 14% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Strong 4 · Adequate 9 · Weak 4. The typical agency here scores Adequate, and 13 of them score higher than this one.

What this dimension measures: Naming fees are famously opaque. Score scope honesty alongside: a firm that states what a naming engagement excludes (identity, strategy, legal filing) is more useful than one implying a full rebrand.

Scores high — Published fees, ranges or stated starting points score 4-5.

Scores low — A stated engagement structure without numbers scores 2-3. Nothing at all scores 1-2.

What we found — No fee, range, starting point or engagement-size figure appears anywhere on the firm's own site across the eight pages read; the Rx and device pages route all commercial questions to contact@brandinstitute.com or +1 305-374-2500. The only pricing signal located is third-party: the Clutch profile, read first-hand, lists a minimum project size of $5,000+ and indicates most reviewed projects fell in the $50,000-$199,999 band. A directory minimum is not the firm publishing a fee. Partly offset by genuine scope honesty - the six service lines (strategy, name development, trademark searches, market research, regulatory, visual identity) are presented as separately commissioned, so a buyer can see that naming, trademark work and visual identity are distinct purchases rather than one implied full rebrand. That separation is why this lands at Weak rather than Poor. That is what the low band describes, which is why it scored Weak.

On the record — “No fee, price range, starting point or engagement timeline appears on any of the eight first-party pages read; commercial enquiries route to contact@brandinstitute.com or +1 305-374-2500.” brandinstitute.com ↗

On the record — “Clutch profile shows 5.0 out of 5 from 3 verified reviews, cost rated 4.8, and a stated minimum project size of $5,000+, with most reviewed projects in the $50,000-$199,999 band.” clutch.co ↗

Evidence: partly checkable — corroborated in part against the sources below; the remainder rests on the agency’s own account.

Stronger here: Tanj scores Strong on the same dimension.

Adequate — 3 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 10% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Strong 4 · Adequate 8 · Weak 5. The typical agency here scores Adequate, and 4 of them score higher than this one.

What this dimension measures: What the client actually receives: how many candidate names per round, how many rounds, what accompanies them (rationale, screening results, territory map), and what happens if every candidate dies in legal.

Scores high — A stated structure with a stated contingency for clearance failure scores 4-5.

Scores low — Undefined deliverables score 2 — in a category where the visible output is a shortlist, not knowing its size before contracting is buying blind.

What we found — Deliverables are defined in kind but not in quantity: original name candidates, trademark screening results, linguistic evaluation reports, name safety testing via the Drug Safety Institute, and recommendations tiered by regulatory viability. A contingency for clearance failure is stated, which is rare in this category - the Rx name development page commits that 'We guarantee a partnership until your compound name is approved. Period.' Kept at Adequate rather than the top band because the shortlist size is never stated: no page gives candidates per round or the number of rounds, so a buyer cannot know the size of the visible output before contracting. The approval guarantee is also unquantified - it does not say whether continued work carries additional fees, which is the part that determines what the commitment is actually worth. That is between the two bands, which is why it scored Adequate.

On the record — “A contingency for regulatory clearance failure is stated in writing: 'We guarantee a partnership until your compound name is approved. Period.' No price or scope limit is attached to that commitment.” brandinstitute.com ↗

deliverability — deliverability: whether cold email actually lands in the inbox rather than spam. The tell is infrastructure talk — warmed sending domains kept separate from your main domain — because a burned domain outlasts the engagement.

Evidence: vendor stated — the agency’s own claim, recorded as theirs rather than ours.

Weak — 2 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 10% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Excellent 1 · Strong 5 · Adequate 4 · Weak 7. The typical agency here scores Adequate, and 10 of them score higher than this one.

What this dimension measures: Stated engagement timelines from kickoff to final candidates.

Scores high — Published, realistic timelines score 4-5 — naming projects run weeks, not days, and honesty beats speed.

Scores low — Undisclosed scheduling scores 2.

What we found — No engagement timeline is published on any page read - no kickoff-to-candidates duration, no stage lengths, no indication of how long regulatory name safety review adds to a project, which is the schedule question that matters most for a pharma naming buy given the multi-year approval cycle. The only scheduling evidence is second-hand and unquantified: Clutch reviewers describe 'well defined timelines' and note the firm handled 'complex and time-sensitive projects,' and all three rate schedule 5.0. That speaks to reliability against a schedule, not to a schedule a prospective buyer can see before contracting. Undisclosed scheduling scores at the rubric's stated floor. That is what the low band describes, which is why it scored Weak.

Evidence: inferred — our reading of indirect evidence, not a documented fact.

Stronger here: River + Wolf scores Excellent on the same dimension.

Adequate — 3 of 5 on this rubric’s scale, from Poor (1) to Excellent (5). This dimension carries 10% of the total score.

Benchmark — across the 17 other agencies evaluated in this discipline, this dimension runs Excellent 9 · Strong 1 · Adequate 5 · Weak 2. The typical agency here scores Excellent, and 10 of them score higher than this one.

What this dimension measures: Independent, verified reviews or checkable client references. Low weight deliberately: boutique naming firms run on referral and small annual project counts, so a thin review footprint is normal and the in-market names matter more.

Scores low — A substantial verified base scores 4-5; a handful scores 2-3; none scores 2.

What we found — The Clutch profile was read first-hand: 5.0 out of 5 overall from 3 verified reviews, with cost rated 4.8. Reviewers cite the balance between creativity and regulatory knowledge, access to ex-FDA reviewers, well-organized projects, and expertise on complex time-sensitive work; no reviewer identified an area for improvement. Three reviews is a handful, not a substantial base, which is the rubric's 2-3 band - and the rubric weights this at 0.05 precisely because a thin review footprint is normal for a firm running a small number of large annual engagements. Supplemented by dated press releases naming client companies, which function as checkable references of a different kind. Note that the claim of a Clutch #1 naming-agency ranking surfaced in search snippets and was not confirmed on the Clutch profile itself, so it is not counted here.

On the record — “Clutch profile shows 5.0 out of 5 from 3 verified reviews, cost rated 4.8, and a stated minimum project size of $5,000+, with most reviewed projects in the $50,000-$199,999 band.” clutch.co ↗

Evidence: verified — checked against a named source you can open; the links under Sources below are where to check it yourself.